
    
      This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group,
      efficacy and safety study of ciclesonide nasal aerosol administered once daily to male and
      premenarchal female subjects 6 to 11 years of age with a diagnosis of PAR. This study will
      consist of the following periods/visits: Screening , Single-blind Placebo Run-in period,
      Double-blind Treatment period , Follow-up. The total duration of subject participation will
      be approximately 5 months.
    
  